Category Archives: Biotechnology

NormanObserver.com

Puma Biotechnology, Inc. (PBYI): What's the Story? StockNewsJournal Puma Biotechnology, Inc. (PBYI) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $80.25, up from yesterday's close by 2.23%. Given the stock's recent action, it ... Puma Biotechnology Inc (PBYI) Soars 7.73% on June 22Equities.com Royal Bank Of Canada Increases Puma Biotechnology Inc (PBYI) Price Target to $60.00The Cerbat Gem The Puma Biotechnology Inc (PBYI) Receives Consensus Rating of Buy from AnalystsBangaloreWeekly Post Analyst -Sports Perspectives -Transcript Daily -SEC.gov all 70 news articles »

Link:
Puma Biotechnology, Inc. (PBYI): What's the Story? - StockNewsJournal

German oncologists have unveiled that market-approved inhibitors of DNA methyltransferases (DMNTi) and histone deacetylases (HDACi) act through expression of cancer neoantigens. They already have a biomarker test to identify responders.

The findings, reported in Nature Genetics, are good news for drug developers who want to broaden the scope of current immune checkpoint modulators through combination therapies that trigger cancer cells to release immunogenic neoantigens.

Following addition of epigenetic inhibitors to cancer cell cultures thousands of atypical transcripts with altered frameshift were expressed form previously ignored endogenous promotors of retroviral origin, resulting in profound tumour cell death, group leader Plass from German Cancer Centre told European Biotechnology. His team has already a biomarker assay that could identify responders to the treatment as it measures activation of the normally silent treatment induced, not-annotated transcription start sites (TINATs).

Up to now, pharma majors such as Roche/Genentech have largely relied on combination of their checkpoint inhibitors with personalised mRNA cancer vaccines. The new findings might open the avenue to a broader activation of cancer neoantigens than these vaccinesas over 2,500 TINATs have been identified in the human genome by the researchers. The retrotransposons (elements of human endogenous retroviruses, HERVs), which are located in long terminal repeats, have entered the human genome millions of years ago.

However, application of the findings might be hampered by the fact that TINATs, so far, have only been identified in the human genome, which might complicate preclinical in-vivo testing. Its unclear if they also exist in animals, says Plass, who is currently deciphering the exact mechanism that normally stops TINATs from being activated. First findings suggest that acetylation of transcription factors might play an important role.

View post:
Epigenetic drugs set to boost immunoncology - European Biotechnology

Eli Lilly has added a new state-of-the-art laboratory and 180,000 square feet of additional working space to its Biotechnology Center in San Diego, CA. Reporting completion of the $90-million expansion, Lilly said the 145% increase in working space will help to foster collaborations with external partners, and allow closer partnerships between its biotechnology, discovery chemistry, and research technology teams. The aim is to accelerate drug discovery within therapeutic areas including immunology, diabetes, oncology, neurodegeneration, and pain.

To further exploit its expertise in automated organic synthesis, and build on its Automated Synthesis Laboratory in Indianapolis, Lilly is also establishing the Lilly Life Science Studio at the San Diego site. The firm says the new facility will give researchers worldwide the ability to remotely test new ideas, and design, synthesize, and screen molecules.

"Investing in drug discovery and development is critical to maintaining an ecosystem that encourages and promotes innovation, commented Jan Lundberg, Ph.D., executive vice president for science and technology and president of Lilly Research Laboratories. "Expanding our presence in San Diego will not only help us discover and deliver innovative medicines faster, but will also help us achieve our goal of launching 20 new medicines in 10 years."

"This year we announced a commitment to invest $850 million in our U.S. operations based on our potential for growth and the company's long-standing investment in the U.S. market, added David A. Ricks, Lilly's chairman, president, and CEO. "This investment doesn't come without risk. America's biopharmaceutical leadership is driven by a free-market economy that rewards innovation. Today, there are multiple public policy threats to our business that would discourage or reduce our investment in the U.S. and the state. We are committed to working with policymakers and stakeholders to ensure our efforts to deliver new innovative medicines to patients are not threatened."

Lilly set up the San Diego Biotechnology Center, which is sited close to the University of California, San Diego, in 2009, having acquired Applied Molecular Evolution back in 2004.

Earlier this month Lilly reported that it will acquire a pipeline of dual amylin calcitonin receptor agonists (DACRAs) from KeyBiosciencefor the potential treatment of type 2 diabetes and other metabolic disorders.

Link:
Lilly Completes $90M Expansion of San Diego Biotechnology Center - Genetic Engineering & Biotechnology News

Following shrinking sales for its wet AMD drug Lucentis, Novartis is back with convincing Phase III results of its anti-VEGF-A singe chain antibody fragment brolucizumab. In two pivotal studies the drug proved to be non-inferior to Regeneron/Bayers Eylea (aflibercept).

With 25 million patients affected worldwide, age-related macular degeneration (AMD) is a highly lucrative market. For years, Novartis first-in-class drug Lucentis (ranibizumab) was dominant in the large US market, but now Regenerons competing drug Eylea (aflibercept, 2026 sales: US$3.3bn, +24%) has overtaken Lucentis (2016: US$2bn, -11%) in US sales, mostly because it is not administered once monthly as Lucentis, but once every two months and has a lower price (US$1,850 per intravitreal injection).

However, results of two pivotal Phase III studies suggest Novartis could return to its former leadership with its next generation anti-VEGF-A-antibody fragment brolucizumab, which has to be administered only once quarterly. In both trials, the HAWK and the HARRIER study, brolucizumab met the primary endpoint of non-inferiority versus aflibercept in best corrected visual acuity after 48 weeks of treatment and the secondary endpoint of mean change in visual acuity. Whats more, the two drugs had comparable side-effect profiles. Novartis plans to submit a BLA next year. Analysts say the drug could reach the market in 2019 and achieve peak sales of US$2bn if also approved in diabetic retinopathy.

However, both aflibercept and Lucentis are challenged by off-label use of Avastin (bevacizumab) as the full-length originator of the single chain antibodies ranabizumab and brolucizumab and competitor to Regenerons VEGF-A/PDF fusion protein has been shown to be non-inferior at a 30-fold lower price.

The rest is here:
AMD: Novartis challenge Regeneron - European Biotechnology

News Items

According to company officials, the center features a new technologically-advanced laboratory and an additional 180,000 square feet of working space, which is an increase of 145 percent compared to the former facility.

In addition to the center's established presence in preclinical and clinical immunology research, the new space allows for closer partnership between Lilly experts in biotechnology, discovery chemistry and research technologies while also fostering external collaborations.

Lilly's new space will help foster and accelerate the discovery of medicines within the company's core therapeutic areas of immunology, diabetes, oncology and neurodegeneration, as well as the emerging area of pain, company officials explained.

"This year we announced a commitment to invest $850 million in our U.S. operations based on our potential for growth and the company's long-standing investment in the U.S. market," said David A. Ricks, Lilly's chairman, president and chief executive officer. "Today, as part of that commitment, we are pleased to say our research footprint in San Diego has been expanded."

"Investing in drug discovery and development is critical to maintaining an ecosystem that encourages and promotes innovation. Our expansion in San Diego is a prime example of investing in a research success story," said Jan Lundberg, Ph.D., Executive Vice President for Science and Technology & President of Lilly Research Laboratories. "Expanding our presence in San Diego will not only help us discover and deliver innovative medicines faster, but will also help us achieve our goal of launching 20 new medicines in 10 years."

"Congratulations to Lilly on the expansion of its new Biotechnology Center, which will double its drug research and development in San Diego, create high-quality jobs, and encourage collaboration on groundbreaking therapies that improve patient care and lower costs," said Representative Scott Peters. "San Diego's life sciences industry is changing the face of medicine and companies like Lilly are driving this innovation."

The company said it plans an extensive investment in its U.S. Research and Development. Nearly $250 million of Lilly's $850 million capital investments will be dedicated to supporting its research and development centers around the U.S., including the center in San Diego, in 2017. Lilly's other U.S. research centers are located in Indianapolis, Indiana; Cambridge, Massachusetts; New York, New York; and Philadelphia, Pennsylvania.

In 2017, Lilly plans to spend approximately $5 billion on global R&D, nearly $4 billion of which will be invested in U.S. based programs, including projects with many of California's leading biomedical research institutions.

"This investment doesn't come without risk. America's biopharmaceutical leadership is driven by a free-market economy that rewards innovation," said Ricks. "Today, there are multiple public policy threats to our business that would discourage or reduce our investment in the U.S. and the state. We are committed to working with policymakers and stakeholders to ensure our efforts to deliver new innovative medicines to patients are not threatened."

Go here to read the rest:
Eli Lilly and Company Opens Biotechnology Center in San Diego, California - Area Development Online

The Report describe Pharmaceutical & Biotechnology Environmental Monitoring Introduction, product scope, market overview, opportunities, risk, driving force also to analyze the top manufacturers, with sales, revenue, and price, market type and application, with sales market share and growth rate by type, application, from 2017 to 2022

Global Pharmaceutical & Biotechnology Environmental Monitoring Industry 2017 presents an executive level blueprint of the global Pharmaceutical & Biotechnology Environmental Monitoring market. This is an analytical research report that delves into evaluating the dynamics of the global Pharmaceutical & Biotechnology Environmental Monitoring market drawing reference to the key trends shaping the supply-chain pattern of the industry. To study the exhaustive information sourced from detailed primary and secondary research, the analysts of the report have used industry leading analytical tools such as SWOT analysis and Porters five forces. The observation made from the analysis not only helps analysts to compile a comprehensive report on the global Pharmaceutical & Biotechnology Environmental Monitoring market, but the same also assists them to understand the prevailing competitive landscape of the market.

For a study to be beneficial for stakeholders, it should constitute a detailed research on the market competitiveness. For the purpose of the same, the research report profiles the leading and prominent players in the Pharmaceutical & Biotechnology Environmental Monitoring market. Information pertaining to key strategies adopted by these companies has been obtained from their respective financial reports, and a meticulous study on the market trends that has impacted their plan of action. Results achieved from the strategies is analyzed thoroughly in the report to update stakeholders about the trends impacting the market. Key findings of the report on the global Pharmaceutical & Biotechnology Environmental Monitoring market will also help companies operating in the market to identify the growth opportunities to propel their operations.

To provide a comprehensive report of the global Pharmaceutical & Biotechnology Environmental Monitoring market, the study has segmented it on the basis of product types, applications, end-use industries, and geography. The leading geographic segments is identified in the report, which also studies the prospects exhibited by the emerging regional markets. With an aim of presenting a 360 degree overview of the market, the report studies the growth drivers, market restraints, and opportunities in detail. Based on in-depth study, the report presents refined growth forecasts for the Pharmaceutical & Biotechnology Environmental Monitoring market.

An exhaustive qualitative review of the factors accelerating and restraining the growth of the Pharmaceutical & Biotechnology Environmental Monitoring market and approaching opportunities has been deployed. The Pharmaceutical & Biotechnology Environmental Monitoring market has been analyzed based on applications, geographic distribution, and the substantial factors accountable for the rising demand of the Pharmaceutical & Biotechnology Environmental Monitoring market globally have been detailed in this report. The report covers the global Pharmaceutical & Biotechnology Environmental Monitoring market right from its definition to the numerous categorizations of the market as well as its key end-use applications.

Get Free Sample Report:https://www.fiormarkets.com/report-detail/67105/request-sample

The elementary weaknesses and strengths of the leading vendors coupled with the rate of growth for each of the segments of the Pharmaceutical & Biotechnology Environmental Monitoring worldwide market have been conferred after a complete analysis of past and prospective trends, regulatory needs, and technological innovations.

Read the original here:
Global Pharmaceutical & Biotechnology Environmental Monitoring Market 2017 Danaher Corporation, Thermo Fisher ... - Aperture Games

It is critical that humanity meet the food needs of a growing population and relieve the increasing pressures on natural systems. Environmental Defense Fund supports the coexistence of diverse farming systems to ensure a sustainable future for farmers, society, and our environment. Achieving these goals will require a comprehensive strategy that draws on a wide range of approaches and technologies, including biotechnology.

EDF recognizes the use of biotechnology as a legitimate deployment of science in the search for effective solutions, and also recognizes that past deployment of some biotechnology products has caused legitimate concerns. For that reason, we will support or oppose specific biotechnology products or processes based on transparent assessments of their health, environmental, social, and economic risks and benefits.The risks and benefits of biotechnology products will often vary by organism, geography and other variables, and need to be assessed at relevant temporal and spatial scales.

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post:Our position on biotechnology

Go here to see the original:
Environmental Defense Fund: Sustainable farming, feeding growing population require biotechnology - Genetic Literacy Project

San Francisco, California, June 20, 2017: The flourishing growth of the pharmaceutical packaging industry worldwide is the primary growth stimulant of the global ampoules market worldwide. The advent of novel injectable therapies due to research and advancements in the field of biotechnology is also augmenting the market. A report by TMR Research, titled Ampoules Market Global Industry Analysis, Size, Share, Trends, Analysis, Growth, and Forecast 20172025, extensively covers all the vital parameters of the market, including vendor landscape and regional segmentation.

Stringent government regulatory framework and industry standards for pharmaceutical packaging are stoking the growth of the global ampoules market. Strict standards and regulations are compelling manufacturers to elevate their packaging practices such that there is no compromise in terms of efficacy and quality of drugs. The spiraling demand for safer transportation of reactive liquids is also providing a significant push to the global market. Besides this, the increasing usage of ampoules in the food and beverage industry is working in favor of the global market.

On the flip side, dumping of ampoules still remains a major concern among governments and pharmaceutical organizations worldwide. Plastics and glasses are non-degradable and therefore, have impact the environment negatively. The rising environmental concerns are, thus, limiting the market from realizing its utmost potential. Nevertheless, the rising incorporation of sustainable materials such as biodegradable plastics or green plastics in the manufacturing of ampoules is likely to provide a significant momentum to the market in the near future. Furthermore, market participants are increasingly focusing towards product extensions and technological innovations, which is expected to bode well for the growth of the market.

On the basis of geography, the market can be fragmented into Europe, Latin America, North America, Asia Pacific, and the Middle East and Africa. North America and Europe are anticipated to account for a substantial cumulative share in the global ampoules market. Rapid advancements in the biotechnology in these regions are augmenting the applications of ampoules. While developed countries will be major revenue contributors, developing regions will emerge as a strong contender during the review period. Asia Pacific is estimated to witness healthy growth, owing to the robust growth of the pharmaceutical and packaging industry.

Some of the key companies operating in the global market for ampoules are Truking Technology Limited, Bausch-Stroebel, Hunan China Sun Pharmaceutical Machinery Co. Ltd., Shanghai Far-East Pharmaceutical Machinery CO. Ltd., Nipro Glass, SCHOTT, Gujarat Fabricators, Essco Glass, Kishore Group, Ciron Group of Companies, James Alexander Corporation, Kapoor Glass Pvt. Ltd, A. H. Industries, Global Pharmatech, Claris Lifesciences Ltd., and Lifespan Biotech Private Ltd.

Like Loading...

Read more here:
Advancements in Biotechnology to Boost Uptake of Ampoules Worldwide - TMR Research Blog (press release) (blog)

June should be national cancer month.

Each year around this time, oncology groups and Wall Street brokerages hold a rash of conferences where researchers reveal the latest, greatest potential cancer cures.

This year has been no exception. Above all, we learned about remarkable advances in two exciting cancer therapies and three great companies that will benefit.

Heres more detail. (Ive kept the technical language to a minimum.)

Tumors are smart. They know how to trick the immune system into missing them. But scientists are wising up to their tricks. In one evasive strategy, tumors release an enzyme that renders them invisible. If you block the enzyme, your immune system can find tumors and destroy them with the help from cancer drugs. This is the key to an early-stage cancer weapon you should invest in, known as IDO inhibitors.

IDO stands for Indoleamine 2,3-dioxygenase, an enzyme released by tumors to blind the bodys immune system. IDO is a strange drug target, because IDO inhibition by itself has no noticeable anti-cancer effect, says Tanguy Seiwert, a cancer-therapy researcher and medical doctor who teaches at the University of Chicago. Suppressing IDO, however, makes tumors vulnerable.

The best pure play in IDO inhibitors is a company whose shares I own, and have suggested since December 2011 in my stock newsletter, Brush Up on Stocks. Were up 750% in this company since 2011 ($14 to $120). But I think this stock is still a hold because there are bigger gains ahead.

Incyte Corp. INCY, +3.58% just released excellent data on its IDO inhibitor, called epacadostat, at the American Society of Clinical Oncology (ASCO) conference. In combination with cancer therapies from Merck & Co. MRK, +1.13% and Bristol-Myers Squibb Co. BMY, +1.40% it showed excellent results against several kinds of cancer.

It looks really good. I think this was a coming-out party for IDO inhibitors, says Seiwert. Besides effectiveness, one of the main positives is that epacadostat is safe. This means it can be readily used to assist many other cancer drugs. You can add it to a ton of things because the cost is low, in terms of toxicity.

Incyte is an ideal biotech company for investors because it is self-funding. It has a very profitable drug called Jakafi, for a rare blood disorder, which supports research on new drugs like the IDO inhibitor. So investors dodge dilutive financings.

So why hasnt Incytes stock shot up? Investors have three main worries. But they look like false fears.

One bit of fake news circulating is that Incyte showed success, in part, only because it omitted patients from some results, which drove up the percentage of success stories. But this is a dubious critique for two reasons. Even if you included the three patients left out, it would only lower the success rate by a few percentage points, notes J.P. Morgan analyst Cory Kasimov. Second, Incyte offered several separate data sets showing success in many types of cancer, but the omission only affected one subgroup, says Seiwert. I think this was way overblown.

The next fear: Competitor NewLink Genetics Corp. NLNK, +3.27% recently announced Roche AG RHHBY, +0.21% handed back development rights to its IDO, following lousy results in a Roche study. Some investors take this as a sign that IDO is malarkey. But William Blair analyst Katherine Xu thinks this is bullish for Incyte, since it signals a competitor may be gone. NewLinks IDO may have fared poorly because it works differently than Incytes IDO, or because Roche used an extremely sick patient population. Neither scenario reflects poorly on Incyte.

The third knock on Incyte is the one to watch. While Seiwert is impressed with Incytes IDO results, he points out the Phase II results are early-stage, and longer-term studies are needed to learn more about patient survival. Those studies are in the works. Incyte has nine Phase III studies planned with Merck and Bristol-Myers Squibb, says Xu. The outcomes here are key, since about $50 worth of the current $120 Incyte stock price is linked to IDO.

In another key advance in cancer therapy in the past two years, doctors have learned how to extract a patients blood and genetically tweak white blood cells so they override evasive tactics used by tumors.

Then the cells are reproduced in a lab to expand the supply, and put back in the patients body so they can move in for the kill. Hopefully, the cells then continue to proliferate and thrive and stay on hand to fight any more cancer that comes along.

Known as chimeric antigen receptor T-cell therapy (CAR-T), this approach has produced remarkable results against blood cancers in patients who otherwise had almost no hope of survival. CAR-T works by unblocking cancer cell receptors normally sought out by the immune system.

This is one of the most exciting therapies in immunotherapy, said Jae Park, a Memorial Sloan Kettering Cancer Center cancer researcher and medical doctor, at the Jefferies 2017 Global Healthcare Conference in early June.

Probably the best pure play here is Kite Pharma Inc. KITE, +1.64% At the Jefferies conference, Kite CEO Arie Belldegrun showed images of a patients body riddled with tumors, which disappeared about a month after treatment began. The patient showed no sign of the disease a year later.

Kite has a product coming on the market by the end of this year, and probably many more on the way, says Brad Loncar, the cancer research expert behind the Loncar Cancer Immunotherapy CNCR, +2.93% exchange traded fund. This is pretty good progress for a therapy that was considered science fiction two years ago.

I suggested Kite in my stock letter at around $71 on May 17, and I think its still a hold even though it has already risen to $87, because this promises to be a blockbuster therapy. At the time, insiders were big buyers as the stock sold off on news of the death of a patient in one of its studies.

That unfortunate death highlights one of the key risks here. CAR-T patients have died because the therapy can cause brain swelling. Doctors are getting better at staving off adverse side effects, says Park. But they still dont fully understand what causes them, which should raise a yellow flag for investors.

Kite also faces competition from other companies developing CAR-T, including power players like Novartis AG NVS, +0.75% Pfizer Inc. PFE, +0.76% Johnson & Johnson JNJ, -0.21% and GlaxoSmithKline PLC GSK, -0.09% as well as Juno Therapeutics Inc. JUNO, +3.91% Cellectis SA CLLS, +0.00% Adaptimmune Therapeutics PLC ADAP, -0.44% and two privately held companies called Poseida Therapeutics and Nanjing Legend Biotech.

Any of these efforts may pan out nicely, but my pick as a third CAR-T play is bluebird bio BLUE, +3.59% which is partnering with Celgene Corp. CELG, +2.29% Bluebird just announced really impressive results for its CAR-T candidate called bb2121. In early studies, just released at ASCO, this therapy produced an overall response rate of 90% to 100% among hospice-type patients whose cancer was so bad that seven different attempts to cure them, on average, had failed.

To generate efficacy data on this level with an overall very tolerable safety profile is highly impressive, says Kasimov, at J.P. Morgan. With more key updates to come in 2017, we would continue to add to positions in bluebird bio.

At the time of publication, Michael Brush held INCY. Brush has suggested INCY and KITE in his stock newsletter Brush Up on Stocks. Brush is a Manhattan-based financial writer who has covered business for the New York Times and The Economist group, and he attended Columbia Business School in the Knight-Bagehot program.

See original here:
Opinion: Three must-own cancer stocks for your biotechnology portfolio - MarketWatch

Dustin Rhoads of Trumann is participating in Biotechnology Research Internship at Arkansas Biosciences Institute. (Photo provided)

Five Arkansas State University students are pursuing their interest in science this summer through the Biotechnology Research Internship Program at the Arkansas Biosciences Institute (ABI) facility on campus. One of those students, Dustin Rhoads, is from Trumann.

The program provides basic support for A-State undergraduate science majors who want research experience in life sciences or applications of life sciences during the summer of their sophomore or junior years.

Each student is matched with a faculty mentor who is conducting research related to biotechnology or biology from one of several departments and colleges, based largely on the student's interests. Selection also is based on academic credentials.

The students, along with their future plans and comments from their applications are:

Dustin Rhoads plans to go to dental school after completing his degree at A-State. His faculty mentor also is Dr. Malathi Srivatsan.

"I chose to apply for this internship mostly because of my interest in the field," Rhoads said. "Neurology has always been and interest of mine. Furthermore, the research we are doing at Dr. Srivatsan's Lab could be used to help so many people. Neuroregeneration could impact the lives of millions, and to be a part of something that could do that is very special to me. What sparked my interest in science was the way it's completely unique from all other academic fields, it has no sense of complacency, and is forever evolving. Im the kind of person who would rather study how things work as opposed to memorizing hard set facts, so the sciences are definitely for me regarding that aspect. I chose Arkansas State University because growing up I was always around it, almost developing it as a second home before even leaving high school, also accompanied with the report of its programs, made it a complete match for me."

The other students are Madalyn Rose Weiner of Little Rock, Oliver Dozier of Paragould, Kayleigh Nelson of Marion, and Aylin Villalpa-Arroyo of Hidalgo, Mexico.

Each internship is valued at $2,500. The students work 20 hours per week for 10 weeks. An additional $500 is provided to the supporting laboratory for research supplies.

See the article here:
Trumann student starting ABI biotechnology research internship - Democrat Tribune